Device Trial Radar · NCT07058831
Subclinical Atrial Fibrillation Home Monitoring in Hypertensive Patients
Last checked: Nov 19, 2026Latest source record: Jul 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
499
Planned (sponsor's estimate)
Start
Mar 1, 2025
Primary completion
Dec 30, 2025
Study completion Dec 30, 2025
Sponsor
- Lead sponsor
- Cardiovascular Research Center Rosario British SanatoriumAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 10, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Atrial fibrillation is a highly prevalent and incidental arrhythmia, often asymptomatic, and frequently detected incidentally or in association with a stroke. Subclinical atrial fibrillation increases cardioembolic risk, highlighting the need for timely diagnosis. New wireless devices capable of recording heart rhythm, combined with innovative artificial intelligence tools, could be useful in the prediction and detection of this arrhythmia. Objective: to determine the usefulness of home blood pressure and heart rhythm monitoring strategy in the detection of subclinical atrial fibrillation. Methods: observational, cohort, prospective, multicenter study involving 25 researchers from six Latin American countries. Home blood pressure monitoring and single-lead electrocardiogram recording were performed in a population at moderate to high risk of developing atrial fibrillation. A minimum of twenty 30-second electrocardiographic and blood pressure recordings over 7 days using an Omron Complete Hem-7530 T ECG device will be uploaded from a mobile phone app and then sent to a database for analysis. Conclusions: the results of this study can provide a simple and accessible home monitoring system for detecting subclinical atrial fibrillation and for optimizing the predictive capacity of arrhythmia risk scores through deep learning.
Conditions
- Asymptomatic Atrial Fibrillation
Interventions
Home ECG monitoringDevice
The 30-second home ECG tracings will be obtained using the Omron Complete Hem-7530 T ECG device (Omron Healthcare Co., Ltd., Japan). The connection and smartphone app download will be available from Omron Connect free of charge on the Google Play Store: https://play.google.com/store/apps/details?id=jp.co.omron.healthcare.omron\_connect\&hl=es\_419\&pli=1 and on the iOS App Store: https://apps.apple.com/mx/app/omron-connect/id1003177043. Two duplicate ECG recordings will be required daily: the first in the morning before breakfast and taking the prescribed medication, and another in the evening before dinner and taking the afternoon/evening medication. Additional ECG recordings will be required if the patient experiences any symptoms.
Primary outcomes
What the sponsor says the trial is designed to measure.
- new atrial fibrillationTime frame: one year
- The absolute numbers of patients with new atrial fibrillationTime frame: one year
- The percentage of patients with new atrial fibrillationTime frame: one year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
British Sanatorium Cardiovascular Research Center
Rosario, Santa Fe Province, Argentina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.